-
公开(公告)号：US11819518B2
公开(公告)日：2023-11-21
申请号：US17245133
申请日：2021-04-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko Schuster , Janet Peper , Philipp Wagner , Hans-Georg Rammensee
IPC: A61K38/00 , A61K35/17 , C07K14/47 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/725 , C07K16/30 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/574
CPC classification number: A61K35/17 , A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/4727 , C07K14/4748 , C07K14/7051 , C07K16/30 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/57484 , A61K2039/5158 , C12N2310/16 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N2333/70539 , G01N2500/04
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10899820B2
公开(公告)日：2021-01-26
申请号：US16911109
申请日：2020-06-24
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko Schuster , Janet Peper , Kevin Roehle , Phillipp Wagner , Hans-Georg Rammensee
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11345737B1
公开(公告)日：2022-05-31
申请号：US17465460
申请日：2021-09-02
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko Schuster , Janet Peper , Kevin Roehle , Philipp Wagner , Hans-Georg Rammensee
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11214608B2
公开(公告)日：2022-01-04
申请号：US17350964
申请日：2021-06-17
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko Schuster , Janet Peper , Kevin Roehle , Philipp Wagner , Hans-Georg Rammensee
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
5.发明申请公开(公告)号：US20200207832A1
公开(公告)日：2020-07-02
申请号：US16815965
申请日：2020-03-11
Applicant: immatics biotechnologies GmbH
Inventor： Heiko Schuster , Janet Peper , Kevin Roehle , Phillipp Wagner , Hans-Georg Rammensee
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
公开(公告)号：US12065477B2
公开(公告)日：2024-08-20
申请号：US17465426
申请日：2021-09-02
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko Schuster , Janet Peper , Kevin Roehle , Philipp Wagner , Hans-Georg Rammensee
CPC classification number: C07K14/70539 , A61K39/0011 , A61P35/00 , C07K14/4748 , C07K16/2818 , C07K16/2833 , C12Q1/6886 , G16B30/00 , A61K39/00 , A61K2039/892 , C07K2317/34 , C12Q2600/156
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11278571B2
公开(公告)日：2022-03-22
申请号：US17245076
申请日：2021-04-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko Schuster , Janet Peper , Philipp Wagner , Hans-Georg Rammensee
IPC: A61K39/00 , A61K35/17 , C07K14/47 , C07K7/06 , C07K7/08 , C07K14/725 , C07K16/30 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/574
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
8.发明申请公开(公告)号：US20200316126A1
公开(公告)日：2020-10-08
申请号：US16905530
申请日：2020-06-18
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Janet Peper , Philipp Wagner , Hans-Georg Rammensee
IPC: A61K35/17 , C07K14/47 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/725 , C07K16/30 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/574
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
9.发明申请公开(公告)号：US20200316125A1
公开(公告)日：2020-10-08
申请号：US16905499
申请日：2020-06-18
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko Schuster , Janet Peper , Philipp Wagner , Hans-Georg Rammensee
IPC: A61K35/17 , C07K14/47 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/725 , C07K16/30 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/574
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10722538B2
公开(公告)日：2020-07-28
申请号：US16777919
申请日：2020-01-31
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko Schuster , Janet Peper , Philipp Wagner , Hans-Georg Rammensee
IPC: A61K39/00 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/725 , C07K16/30 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/574
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.016 seconds)
